skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis

Original Research

(3231) Views  (907) Full article downloads

Authors: Jette B Kornum, Rikke B Nielsen, Lars Pedersen, et al

Published Date March 2010 Volume 2010:2 Pages 29 - 36
DOI: http://dx.doi.org/10.2147/CLEP.S9256

Jette B Kornum1, Rikke B Nielsen1, Lars Pedersen1, Preben B Mortensen2, Mette Nørgaard1

1Department of Clinical Epidemiology, Aarhus University Hospital, Denmark; 2National Center for Registry-based Research, University of Aarhus, Aarhus, Denmark

Background: Data on the safety of selective serotonin-reuptake inhibitors (SSRIs) in pregnancy are inconsistent. We examined associations between SSRI use during early pregnancy and risk of congenital malformations in infants.

Methods: Set in Northern Denmark, our population-based prevalence study included 216,042 women who had a live birth after the 20th week of gestation. We compared the prevalence of malformation in infants born to women who redeemed at least one SSRI prescription during early pregnancy with the prevalence in infants born to women who redeemed no SSRI prescriptions during their pregnancies. Drug use data were extracted from prescription databases, while data on congenital malformations were obtained from the National Registry of Patients.

Results: The 2,062 women with SSRI prescriptions during early pregnancy gave birth to 105 (5.1%) infants with malformations, while the 213,712 women with no SSRI prescriptions gave birth to 7,449 (3.5%) infants with malformations. SSRI use was associated with an increased risk of malformations overall (odds ratio [OR] = 1.3; 95% confidence interval (CI): 1.1–1.6) and cardiac malformations (OR = 1.7; 95% CI: 1.1–2.5). For specific SSRIs, we found an increased risk for septal defects associated with sertraline.

Conclusions: We found little overall association between use of SSRIs during pregnancy and congenital malformations, but our findings suggest an association between maternal SSRI use in early pregnancy and cardiac malformations which could be causal.

Keywords: antidepressants, drug safety, pregnancy, congenital malformations, epidemiology








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Testing whether drugs that weaken norepinephrine signaling prevent or treat various types of cancer
Ego mechanisms of defense are associated with patients’ preference of treatment modality independent of psychological distress in end-stage renal disease
Can a gentamicin-specific chart reduce neonatal medication errors?
Hepatitis C virus infection and risk of cancer: a population-based cohort study
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
Dashboards in neonatology
Sex ratio of newborn infants born to pregnant women with severe chronic constipation
Everolimus-eluting stents: update on current clinical studies
Helicobacter pylori infection and primary open-angle glaucoma: is there a connection?